A proposed framework for an appropriate evaluation scheme for microorganisms as novel foods with a health claim in Europe

Microbial Cell Factories

Volumn 14, Issue 1, 2015, Pages

  Miquel, Sylvie ^a   Beaumont, Martin ^a   Martín, Rebeca ^a   Langella, Philippe ^a   Braesco, Véronique ^b   Thomas, Muriel ^a  

^a UMR1319 MICALIS   (France)

^b VAB nutrition   (France)

Author keywords

Beneficial microbes; Gastro intestinal (GI) tract; Probiotic; Regulation; Safety

Indexed keywords

PROBIOTIC AGENT; YOGHURT;

ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIUM; BIFIDOBACTERIUM; CLOSTRIDIUM BUTYRICUM; DIET SUPPLEMENTATION; DNA HYBRIDIZATION; FERMENTATION; FOOD INDUSTRY; FOOD SAFETY; FUNCTIONAL FOOD; GENE TRANSFER; HEALTH CARE POLICY; IMMUNE RESPONSE; INTESTINE FLORA; LACTIC ACID BACTERIUM; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII; METABOLISM; MICROENCAPSULATION; MICROENVIRONMENT; NONHUMAN; PANCREAS SECRETION; PULSED FIELD GEL ELECTROPHORESIS; RESTRICTION MAPPING; REVIEW; RISK ASSESSMENT; STREPTOCOCCUS; STREPTOCOCCUS THERMOPHILUS; THROMBOCYTE AGGREGATION; EUROPE; EVALUATION STUDY; FOOD CONTROL; INTESTINE; LAW; MICROBIOLOGY; MICROFLORA; PRACTICE GUIDELINE; PROCEDURES; PRODUCT SAFETY; PUBLIC HEALTH; STANDARDS; TIME FACTOR;

BACTERIA (MICROORGANISMS);

CONSUMER PRODUCT SAFETY; EUROPE; FOOD INSPECTION; FOOD MICROBIOLOGY; GUIDELINES AS TOPIC; INTESTINES; LEGISLATION, FOOD; MICROBIOTA; PUBLIC HEALTH; TIME FACTORS;

EID: 84928266303     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/s12934-015-0229-1     Document Type: Review

References (77)

1. FAO/WHO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001.
2. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-14.
3. Schmidt C. The startup bugs. Nat Biotechnol. 2013;31(4):279-81.
4. Hungin AP, Mulligan C, Pot B, Whorwell P, Agreus L, Fracasso P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. Aliment Pharmacol Ther. 2013;38(8):864-86.
5. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7(4):e34938.
6. Smug LN, Salminen S, Sanders ME, Ebner S. Yoghurt and probiotic bacteria in dietary guidelines of the member states of the European Union. Benef Microbes. 2014;5(1):61-6.
7. Sanders ME, Lenoir-Wijnkoop I, Salminen S, Merenstein DJ, Gibson GR, Petschow BW, et al. Probiotics and prebiotics: prospects for public health and nutritional recommendations. Ann N Y Acad Sci. 2014;1309:19-29.
8. Foligne B, Daniel C, Pot B. Probiotics from research to market: the possibilities, risks and challenges. Curr Opin Microbiol. 2013;16(3):284-92.
9. Bron PA, Tomita S, Mercenier A, Kleerebezem M. Cell surface-associated compounds of probiotic lactobacilli sustain the strain-specificity dogma. Curr Opin Microbiol. 2013;16(3):262-9.
10. Turpin W, Humblot C, Thomas M, Guyot JP. Lactobacilli as multifaceted probiotics with poorly disclosed molecular mechanisms. Int J Food Microbiol. 2010;143(3):87-102.
11. EFSA Panel on Dietetic Products, Nutrition and Allergies NDA. Scientific Opinion on the substantiation of health claims related to live yoghurt cultures and improved lactose digestion (ID 1143, 2976) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal. 2010;8(10):1763.
12. EFSA Panel on Dietetic Products, Nutrition and Allergies NDA. Scientific Opinion on the substantiation of health claims related to non-characterised bacteria and yeasts pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal. 2010;8(2):1470.
13. FAO/WHO. Guidelines for the Evaluation of Probiotics in Food. 2002.
14. Donelli G, Vuotto C, Mastromarino P. Phenotyping and genotyping are both essential to identify and classify a probiotic microorganism. Microb Ecol Health Dis. 2013;24:20105 - http://dx.doi.org/10.3402/mehd.v24i0.20105.
15. Rijkers GT, de Vos WM, Brummer RJ, Morelli L, Corthier G, Marteau P. Health benefits and health claims of probiotics: bridging science and marketing. Br J Nutr. 2011;106(9):1291-6.
16. Kleerebezem M, Vaughan EE. Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity. Annu Rev Microbiol. 2009;63:269-90.
17. Ben-Yahia L, Mayeur C, Rul F, Thomas M. Growth advantage of Streptococcus thermophilus over Lactobacillus bulgaricus in vitro and in the gastrointestinal tract of gnotobiotic rats. Benef Microbes. 2012;3(3):211-9.
18. Delorme C. Safety assessment of dairy microorganisms: Streptococcus thermophilus. Int J Food Microbiol. 2008;126(3):274-7.
19. Herve-Jimenez L, Guillouard I, Guedon E, Gautier C, Boudebbouze S, Hols P, et al. Physiology of Streptococcus thermophilus during the late stage of milk fermentation with special regard to sulfur amino-acid metabolism. Proteomics. 2008;8(20):4273-86.
20. Pineiro M, Stanton C. Probiotic bacteria: legislative framework- requirements to evidence basis. J Nutr. 2007;137(3 Suppl 2):850S-3.
21. Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach J, Hormannsperger G, et al. Safety assessment of probiotics for human use. Gut Microbes. 2010;1(3):164-85.
22. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol. 2012;46(6):468-81.
23. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). General guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal. 2011;9(4):2135.
24. Mitropoulou G, Nedovic V, Goyal A, Kourkoutas Y. Immobilization technologies in probiotic food production. J Nutr Metab. 2013;2013:716861.
25. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13(1):35-7.
26. EFSA Panel on Biological Hazards. Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2013 update). EFSA Journal. 2013;11:3449.
27. Adams MR, Marteau P. On the safety of lactic acid bacteria from food. Int J Food Microbiol. 1995;27(2-3):263-4.
28. Joly F, Mayeur C, Bruneau A, Noordine ML, Meylheuc T, Langella P, et al. Drastic changes in fecal and mucosa-associated microbiota in adult patients with short bowel syndrome. Biochimie. 2010;92(7):753-61.
29. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65.
30. Marteau P. Safety aspects of probiotic products. Scand J Nutr. 2001;45:22-4.
31. Salminen S, von Wright A, Morelli L, Marteau P, Brassart D, de Vos WM, et al. Demonstration of safety of probiotics - a review. Int J Food Microbiol. 1998;44(1-2):93-106.
32. Silley P. Do bacteria need to be regulated? J Appl Microbiol. 2006;101(3):607-15.
33. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol. 2009;44(1):26-46.
34. Mater DD, Bretigny L, Firmesse O, Flores MJ, Mogenet A, Bresson JL, et al. Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus survive gastrointestinal transit of healthy volunteers consuming yogurt. FEMS Microbiol Lett. 2005;250(2):185-7.
35. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453(7195):620-5.
36. Macho Fernandez E, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut. 2011;60(8):1050-9.
37. Riaz QU, Masud T. Recent trends and applications of encapsulating materials for probiotic stability. Crit Rev Food Sci Nutr. 2013;53(3):231-44.
38. Vyas U, Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterol Res Pract. 2012;2012:872716.
39. Grill JP, Perrin S, Schneider F. Bile salt toxicity to some bifidobacteria strains: role of conjugated bile salt hydrolase and pH. Can J Microbiol. 2000;46(10):878-84.
40. Begley M, Hill C, Gahan CG. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol. 2006;72(3):1729-38.
41. EFSA Panel on Additives and Products, or Substances used in Animal Feed FEEDAP. Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. EFSA Journal. 2012;10(6):2740.
42. Bayliss CE, Houston AP. Characterization of plant polysaccharide- and mucin-fermenting anaerobic bacteria from human feces. Appl Environ Microbiol. 1984;48(3):626-32.
43. Wrzosek L, Miquel S, Noordine ML, Bouet S, Chevalier-Curt MJ, Robert V, et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 2013;11:61.
44. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066-71.
45. Guidance for Industry. Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information. http://wwwfdagov/downloads/BiologicsBloodVaccines/Guidance-ComplianceRegulatoryInformation/Guidances/General/UCM292704pdf February 2012.
46. McNulty NP, Yatsunenko T, Hsiao A, Faith JJ, Muegge BD, Goodman AL, et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med. 2011;3(106):106ra106.
47. Hapfelmeier S, Lawson MA, Slack E, Kirundi JK, Stoel M, Heikenwalder M, et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science. 2010;328(5986):1705-9.
48. Turpin W, Humblot C, Noordine ML, Thomas M, Guyot JP. Lactobacillaceae and cell adhesion: genomic and functional screening. PLoS One. 2012;7(5):e38034.
49. Ledoux D, Labombardi VJ, Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int J STD AIDS. 2006;17(4):280-2.
50. Mack DR. D(-)-lactic acid-producing probiotics, D(-)-lactic acidosis and infants. Can J Gastroenterol. 2004;18(11):671-5.
51. Mayeur C, Gratadoux JJ, Bridonneau C, Chegdani F, Larroque B, Kapel N, et al. Faecal D/L lactate ratio is a metabolic signature of microbiota imbalance in patients with short bowel syndrome. PLoS One. 2013;8(1):e54335.
52. Duncan SH, Louis P, Flint HJ. Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl Environ Microbiol. 2004;70(10):5810-7.
53. de Vrese M, Barth CA. Postprandial plasma D-lactate concentrations after yogurt ingestion. Z Ernahrungswiss. 1991;30(2):131-7.
54. European Commission Health and Consumer Protection Directorate-General, Scientific Committee on Animal Nutrition (SCAN). Opinion of the scientific committee on animal nutrition on the safety of use of Bacillus species in animal nutrition. 2000.
55. Al Kassaa I, Hamze M, Hober D, Chihib NE, Drider D. Identification of vaginal lactobacilli with potential probiotic properties isolated from women in North Lebanon. Microb Ecol. 2014;67(3):722-34.
56. Del Turco S, Sartini S, Cigni G, Sentieri C, Sbrana S, Battaglia D, et al. Synthetic analogues of flavonoids with improved activity against platelet activation and aggregation as novel prototypes of food supplements. Food Chem. 2015;175:494-9.
57. Suslova TE, Sitozhevskii AV, Ogurkova ON, Kravchenko ES, Kologrivova IV, Anfinogenova Y, et al. Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation. Front Physiol. 2015;5:501.
58. Bangemann M. 97/618/CE: Recommandation de la Commission du 29 juillet 1997. Journal officiel. 1997;L 253:1-36.
59. de Graaf IA, Olinga P, de Jager MH, Merema MT, de Kanter R, van de Kerkhof EG, et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc. 2010;5(9):1540-51.
60. Leushacke M, Barker N. Ex vivo culture of the intestinal epithelium: strategies and applications. Gut. 2014;63(8):1345-54.
61. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Guidance on the scientific requirements for health claims related to gut and immune function. EFSA Journal. 2011;9(4):12.
62. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health. EFSA Journal. 2011;9(12):13.
63. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations. EFSA Journal. 2011;10(3):11.
64. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-14.
65. Aziz Q, Dore J, Emmanuel A, Guarner F, Quigley EM. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil. 2013;25(1):4-15.
66. Cherbuy C, Honvo-Houeto E, Bruneau A, Bridonneau C, Mayeur C, Duee PH, et al. Microbiota matures colonic epithelium through a coordinated induction of cell cycle-related proteins in gnotobiotic rat. Am J Physiol Gastrointest Liver Physiol. 2010;299(2):G348-57.
67. Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, Bridonneau C, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009;31(4):677-89.
68. Tomas J, Reygner J, Mayeur C, Ducroc R, Bouet S, Bridonneau C, et al. Early colonizing Escherichia coli elicits remodeling of rat colonic epithelium shifting toward a new homeostatic state. ISME J. 2015;9(1):46-58.
69. Tomas J, Wrzosek L, Bouznad N, Bouet S, Mayeur C, Noordine ML, et al. Primocolonization is associated with colonic epithelial maturation during conventionalization. Faseb J. 2013;27(2):645-55.
70. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107(33):14691-6.
71. Miquel S, Martin R, Bridonneau C, Robert V, Sokol H, Bermudez-Humaran LG, et al. Ecology and metabolism of the beneficial intestinal commensal bacterium. Gut Microbes. 2014;5(2):146-51.
72. Miquel S, Martin R, Rossi O, Bermudez-Humaran LG, Chatel JM, Sokol H, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013;16(3):255-61.
73. Martin R, Chain F, Miquel S, Lu J, Gratadoux JJ, Sokol H, et al. The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm Bowel Dis. 2014;20(3):417-30.
74. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731-6.
75. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541-6.
76. van Loveren H, Sanz Y, Salminen S. Health claims in Europe: probiotics and prebiotics as case examples. Annu Rev Food Sci Technol. 2012;3:247-61.
77. Arnold C. The pros and cons of probiotics. Lancet Infect Dis. 2013;13(7):571-2.